The role of low-grade inflammation in the polycystic ovary syndrome

Molecular and Cellular Endocrinology

Volumn 335, Issue 1, 2011, Pages 30-41

  Repaci, Andrea ^a   Gambineri, Alessandra ^a   Pasquali, Renato ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Adipo cytokines; Adipose tissue; Androgens; Insulin resistance; PCOS

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANDROGEN; ANGIOTENSIN II; ATORVASTATIN; C REACTIVE PROTEIN; CHEMOKINE; CYTOKINE; FATTY ACID; FERRITIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; INTERLEUKIN 18; INTERLEUKIN 1BETA; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OSTEOPROTEGERIN; RANTES; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ABDOMINAL OBESITY; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL INTERACTION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; FATTY ACID BLOOD LEVEL; HUMAN; HYPERANDROGENISM; INFLAMMATION; INSULIN RESISTANCE; LIPID OXIDATION; LIPOLYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; STIMULUS RESPONSE; THROMBOCYTE ADHESION; VASCULARIZATION; VASOCONSTRICTION; VASODILATATION;

ADIPOKINES; ANDROGENS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CYTOKINES; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERANDROGENISM; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN RESISTANCE; MALE; OBESITY; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, GENETIC;

EID: 79951576067     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.08.002     Document Type: Review

References (206)

1. Anderson E.A., Mark A.L. Flow-mediated and reflex changes in large peripheral artery tone in human. Circulation 1989, 79(1):93-100.
2. Ando H., Takamura T., Ota T., Nagai Y., Kobayashi K. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J. Pharmacol. Exp. Ther. 2000, 294:1043-1046.
3. Azziz R., Woods K.S., Reyna R., Key T.J., Knochenhauer E.S., Yildiz B.O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 2004, 89(6):2745-2749.
4. Baeuerle P.A., Henkel T. Function and activation of NF-kappa B in the immune system. Annu. Rev. Immunol. 1994, 12:141-179.
5. Banaszewska B., Pawelczyk L., Spaczynski R.Z., Duleba A.J. Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. J. Clin. Endocrinol. Metab. 2009, 94:1-8.
6. Barter P.J., Kastelein J.J. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J. Am. Coll. Cardiol. 2006, 47(3):492-499.
7. Bell L.N., Cai L., Johnstone B.H., Traktuev D.O., March K.L., Considine R.V. A central role for hepatocyte growth factor in adipose tissue angiogenesis. Am. J. Physiol. Endocrinol. Metab. 2008, 294(2):E336-E344.
8. Beltowski J., Jamroz-Wisniewska A., Borkowska E., Wojcicka G. Up-regulation of renal Na{thorn}, K{thorn}-ATPase: the possible novel mechanism of leptin-induced hypertension. Pol. J. Pharmacol. 2004, 56(2):213-222.
9. Benson S., Janssen O.E., Hahn S., et al. Obesity, depression and chronic low-grade inflammation in women with polycystic ovary syndrome. Brain Behav. Immun. 2008, 22(2):177-184.
10. Blankenberg S., Tiret L., Bickel C., et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002, 106(1):24-30.
11. Bogaert Y.E., Linas S. The role of obesity in the pathogenesis of hypertension. Nat. Clin. Pract. Nephrol. 2009, 5(2):101-111.
12. Boger R.H. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann. Med. 2006, 38(2):126-136.
13. Boord J.B., Fazio S., Linton M.F. Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis. Curr. Opin. Lipidol. 2002, 13(2):141-147.
14. Botella-Carretero J.I., Luque-Ramirez M., Alvarez-Blasco F., San Millan J.L., Escobar-Morreale H.F. Mutations in the hereditary hemochromatosis gene are not associated with the increased body iron stores observed in overweight and obese women with polycystic ovary syndrome. Diabetes Care 2006, 29(11):2556.
15. Boulman N., Levy Y., Leiba R., et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J. Clin. Endocrinol. Metab. 2004, 89(5):2160-2165.
16. Brahimi-Horn M.C., Pouyssegur J. Oxygen, a source of life and stress. FEBS Lett. 2007, 581(19):3582-3591.
17. Brunner H., Cockcroft J.R., Deanfield J., et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J. Hypertens. 2005, 23(2):233-246.
18. Brzechffa P.R., Jakimiuk A.J., Agarwal S.K., Weitsman S.R., Buyalos R.P., Magoffin D.A. Serum immunoreactive leptin concentrations in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1996, 81(11):4166-4168.
19. Calandra T., Bernhagen J., Metz C.N., et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995, 377(6544):68-71.
20. Cancello R., Henegar C., Viguerie N., et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005, 54(8):2277-2286.
21. Carmina E., Orio F., Palomba S., et al. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am. J. Med. 2006, 119(4). 356:e1-e6.
22. Carmina E., Bucchieri S., Mansueto P., Rini G., Ferin M., Lobo R.A. Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome. Fertil. Steril. 2009, 91(4 Suppl.):1332-1335.
23. Caslake M.J., Packard C.J. Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curr. Opin. Lipidol. 2003, 14(4):347-352.
24. Castrogiovanni D., Perello M., Gaillard R.C., Spinedi E. Modulatory role of testosterone in plasma leptin turnover in rats. Endocrine 2003, 22(3):203-210.
25. Chen C.H. Platelet-activating factor acetylhydrolase: is it good or bad for you?. Curr. Opin. Lipidol. 2004, 15(3):337-341.
26. Chen M.J., Yang W.S., Yang J.H., Chen C.L., Ho H.N., Yang Y.S. Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome. Hypertension 2007, 49(6):1442-1447.
27. Cinti S., Mitchell G., Barbatelli G., et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 2005, 46(11):2347-2355.
28. Corti R., Hutter R., Badimon J.J., Fuster V. Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J. Thromb. Thrombolysis 2004, 17(1):35-44.
29. Cortón M., Botella-Carretero J.I., Benguría A., et al. Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2007, 92(1):328-337.
30. Costa L.O., Dos Santos M.P., Oliveira M., Viana A. Low-grade chronic inflammation is not accompanied by structural arterial injury in polycystic ovary syndrome. Diabetes Res. Clin. Pract. 2008, 81(2):179-183.
31. Dahlgren E., Janson P.O., Johansson S., Lapidus L., Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet. Gynecol. Scand. 1992, 71(8):599-604.
32. Dandona P., Aljada A., Ghanim H., et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J. Clin. Endocrinol. Metab. 2004, 89(10):5043-5047.
33. Death A.K., McGrath K.C., Sader M.A., et al. Dihydrotestosterone promotes vascular cell adhesion molecule-1 expression in male human endothelial cells via a nuclear factor-kappaB-dependent pathway. Endocrinology 2004, 145(4):1889-1897.
34. Diamanti-Kandarakis E., Spina G., Kouli C., Migdalis I. Increase in endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin treatment. J. Clin. Endocrinol. Metab. 2001, 86(10):4666-4673.
35. Diamanti-Kandarakis E., Alexandraki K., Protogerou A., et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur. J. Endocrinol. 2005, 152(5):749-756.
36. Diamanti-Kandarakis E., Piperi C., Kalofoutis A., Creatsas G. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin. Endocrinol. 2005, 62(1):37-43.
37. Diamanti-Kandarakis E., Paterakis T., Alexandraki K., et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and beneficial effect of metformin. Hum. Reprod. 2006, 21(6):1426-1431.
38. Diamanti-Kandarakis E., Alexandraki K., Piperi C., et al. Inflammatory and endothelial marker in women with polycystic ovary syndrome. Eur. J. Clin. Invest. 2006, 36(10):691-697.
39. Diamanti-Kandarakis E., Katsikis I., Piperi C., et al. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin. Endocrinol. (Oxf.) 2008, 69(4):634-641.
40. Duleba A.J., Banaszweska B., Spaczynski R.Z., Pawelczyk L. Simvastatin improves biochemical parameters of polycystic ovary syndrome: results of a prospective randomized trial. Fertil. Steril. 2006, 85:996-1001.
41. Dunger A., Cunningham J.M., Delaney C.A., et al. Tumor necrosis factor-alpha and interferon-gamma inhibit insulin secretion and cause DNA damage in unweaned-rat islets. Extent of nitric oxide involvement. Diabetes 1996, 45(2):183-189.
42. Eckel R.H., Yost T.J., Jensen D.R. Alterations in lipoprotein lipase in insulin resistance. Int. J. Obes. Relat. Metab. Disord. 1995, 19(Suppl. 1):S16-S21.
43. Ehrmann D.A. Polycystic ovary syndrome. N. Engl. J. Med. 2005, 352(12):1223-1236.
44. Ehrmann D.A., Barnes R.B., Rosenfield R.L., Cavaghan M.K., Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999, 22(1):141-146.
45. El Orabi H., Ghalia A.A., Khalifa A., Mahfouz H., El Shalkani A., Shoieb N. Serum leptin as an additional possible pathogenic factor in polycystic ovary syndrome. Clin. Biochem. 1999, 32(1):71-75.
46. Elbers J.M., Asscheman H., Seidell J.C., Frolich M., Meinders A.E., Gooren L.J. Reversal of the sex difference in serum leptin levels upon cross-sex hormone administration in transsexuals. J. Clin. Endocrinol. Metab. 1997, 82(10):3267-3270.
47. Emery J.G., McDonnell P., Burke M.B., et al. Osteoprotegerin is a receptor for cytotoxic ligand TRAIL. J. Biol. Chem. 1998, 273(23):14363-14367.
48. Escobar-Morreale H.F., Calvo R.M., Sancho J., San Millàn J.L. TNF-a and hyperandrogenism: a clinical, biochemical and molecular genetic study. J. Clin. Endocrinol. Metab. 2001, 86(8):3761-3767.
49. Escobar-Morreale H.F., Calvo R.M., Villuendas G., Sancho J., San Millàn J.L. Association of polymorphism in the interleukin 6 receptor complex with obesity and hyperandrogenism. Obes. Res. 2003, 11(8):987-996.
50. Escobar-morreale H.F., Botella-carretero J.I., Villuendas G., Sancho J., San Millán J.L. Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J. Clin. Endocrinol. Metab. 2004, 89(2):806-811.
51. Escobar-Morreale H.F., Luque-Ramirez M., Alvarez-Blasco F., Botella-Carretero J.I., Sancho J., San Millán J.L. Body iron stores are increased in overweight and obese women with polycystic ovary syndrome. Diabetes Care 2005, 28(8):2042-2044.
52. Escobar-Morreale H.F., Botella-Carretero J.I., Martinez-Garcia M.A., Luque-Ramirez M., Alverez-Blasco F., San Millàn J.L. Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome. Eur. J. Endocrinol. 2008, 159(3):225-232.
53. Esposito K., Pontillo A., Ciotola M., et al. Weight loss reduces interleukin-18 levels in obese women. J. Clin. Endocrinol. Metab. 2002, 87(8):3864-3866.
54. Fagerberg B., Hulten L.M., Hulthe J. Plasma ghrelin, body fat, insulin resistance, and smoking in clinically healthy men: the atherosclerosis and insulin resistance study. Metabolism 2003, 52(11):1460-1463.
55. Fan P., Liu H.W., Wan D.H., Li Y., Song Q., Bai H. Altered distribution of plasma platelet-activating factor acetylhydrolase between high-density lipoprotein and low-density lipoprotein in patients with polycystic ovary syndrome. Fertil. Steril. 2009, 92(6):2054-2057.
56. Fenkci V., Fenkci S., Yilmazer M., Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil. Steril. 2003, 80(1):123-127.
57. Fernandez-Real J.M., Lopez-Bermejo A., Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 2002, 51(8):2348-2354.
58. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438(7070):967-974.
59. Fujioka S., Matsuzawa Y., Tokunaga K., Tar ui S. Contribution of intraabdominal fat accumulation to the impairment of glucose and lipid metabolism. Metabolism 1987, 36(1):54-59.
60. Gambineri A., Pagotto U., Tschöp M., et al. Anti-androgen treatment increase circulating ghrelin levels in obese women with polycystic ovary syndrome. J. Endocrinol. Invest. 2003, 26(7):629-634.
61. Gambineri A., Pelusi C., Manicardi E., et al. Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes 2004, 53(9):2353-2358.
62. Gambineri A., Repaci A., Patton L., et al. Prominent role of low HDL-cholesterol in explaining the high prevalence of the metabolic syndrome in polycystic ovary syndrome. Nutr. Metab. Cardiovasc. Dis. 2009, 19(11):797-804.
63. Gen R., Akbay E., Muslu N., Sezer K., Cayan F. Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance. Gynecol. Endocrinol. 2009, (4):241-245.
64. Glintborg D., Andersen M., Hagen C., et al. Evaluation of the metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute patients and control. Eur. J. Endocrinol. 2006, 155(2):337-345.
65. Glintborg D., Andersen M., Richelsen B., Bruun J. Plasma monocyte chemoattractant protein-1 and macrophage inflammatory protein-1a are increased in patients with polycystic ovary syndrome and associated with adiposity, but unaffected by pioglitazone treatment. Clin. Endocrinol. 2009, 71(5):652-658.
66. Glud T., Schnidt E.B., Kristensen S.D., Arnfred T. Platelet number and volume during myocardial infarction in relation to infarct size. Acta Med. Scand. 1986, 220(5):401-405.
67. Gomez-Ambrosi J., Salvador J., Paramo J.A., et al. Involvement of leptin in the association between percentage of body fat and cardiovascular risk factors. Clin. Biochem. 2002, 35(4):315-320.
68. Gonzalez F., Thusu K., Abdel-Rahman E., Prabhala A., Tomani M., Dandona P.K. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metabolism 1999, 48(4):437-441.
69. Gonzalez F., Rote N.S., Minium J., Kirwan J.P. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism. J. Clin. Endocrinol. Metab. 2006, 91(1):336-340.
70. Gonzalez F., Rote N.S., Minium J., Kirwan J.P. Increased activation of nuclear factor kB triggers inflammation and insulin resistance in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2006, 91(4):1508-1512.
71. Gonzalez F., Rote N.S., Minium J., Kirwan J.P. Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metabolism 2009, 58(7):954-962.
72. Goossens G.H., Blaak E.E., Saris W.H., van Baak M.A. Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects. J. Clin. Endocrinol. Metab. 2004, 89(6):2690-2696.
73. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3(1):23-35.
74. Guzelmeric K., Alkan N., Pirimoglu M., Unal O., Turan C. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome. Gynecol. Endocrinol. 2007, 23(9):505-510.
75. Guzick D.S., Talbott E.O., Sutton-Tyrrell K., Herzog H.C., Kuller L.H., Wolfson S.K. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am. J. Obstet. Gynecol. 1996, 174(4):1224-1229.
76. Hajer G.R., van Haeften T.W., Visseren F.L.J. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur. Heart J. 2008, 29:2959-2971.
77. Heutling D., Schulz H., Nickel I., Kleinstein J., Kaltwasser P., Westphal S., et al. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women polycystic ovary syndrome before and after metformin treatment. J. Clin. Endocrinol. Metab. 2008, 93(1):82-90.
78. Hislop M.S., Ratanjee B.D., Soule S.G., Marais A.D. Effects of anabolicandrogenic steroid use or gonadal testosterone suppression on serum leptin concentration in men. Eur. J. Endocrinol. 1999, 141(1):40-46.
79. Holecki M., Zahorska-Markiewicz B., Janowska J., et al. The influence of weight loss on serum osteoprotegerin concentration in obese perimenopausal women. Obesity 2007, 15(8):1925-1929.
80. Hosogai N., Fukuhara A., Oshima K., et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007, 56(4):901-911.
81. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444(7121):860-867.
82. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 1995, 95(5):2409-2415.
83. Hu W.H., Qiao J., Zhao S.Y., Zhang X.W., Li M.A. Monocyte chemoattractant protein-1 and its correlation with lipoprotein in polycystic ovary syndrome. Beijing Da Xue Xue Bao 2006, 38(5):487-491.
84. Ibanez L., Jaramillo A.M., Ferrer A., de Zegher F. High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception. Hum. Reprod. 2005, 20(9):2457-2462.
85. Isoda K., Young J.L., MacFarlane L.A., Tsuboi N., Gerdes N., Schönbeck U., Libby P. Metformin inhibits proinflammatory responses and nuclear factor-kB in human vascular wall cells. Arterioscler. Thromb. Vasc. Biol. 2006, 26:611-617.
86. Jansson P.A., Larsson A., Lonnroth P.N. Relationship between blood pressure, metabolic variables and blood flow in obese subjects with or without non-insulin-dependent diabetes mellitus. Eur. J. Clin. Invest. 1998, 28(10):813-818.
87. Kado S., Nagata N. Circulating intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin in patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 1999, 46(2):143-148.
88. Kaipia A., Chun S.Y., Eisenhauer K., Hsueh A.J. Tumor necrosis factor-alpha and its second messenger, ceramide, stimulate apoptosis in cultured ovarian follicles. Endocrinology 1996, 137(11):4864-4870.
89. Kanai H., Matsuzawa Y., Kotani K., et al. Close correlation of intraabdominal fat accumulation to hypertension in obese women. Hypertension 1990, 16(5):484-490.
90. Karadeniz M., Erdogan M., Tamsel S., et al. Oxidative stress markers in young patients with polycystic ovary syndrome, the relationship between insulin resistances. Exp. Clin. Endocrinol. Diabetes 2008, 116(4):231-235.
91. Karadeniz M., Erdogan M., Zengi A., et al. Polymorphism of the interleukin-10 gene in polycystic ovary syndrome. Int. J. Immunogenet. 2008, 35(2):119-123.
92. Karasawa K. Clinical aspects of plasma platelet-activating factor-acetylhydrolase. Biochim. Biophys. Acta 2006, 1761(11):1359-1372.
93. Karpe F., Fielding B.A., Ilic V., Macdonald I.A., Summers L.K., Fr ayn K.N. Impaired postprandial adipose tissue blood flow response is related to aspects of insulin sensitivity. Diabetes 2002, 51(8):2467-2473.
94. Kebapcillar L., Taner C.E., Kebapcillar A.G., Sari I. High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome. Arch. Gynecol. Obstet. 2009, 280(2):187-193.
95. Kelly C.C., Lyall H., Petrie J.R., et al. Low-grade chronic inflammation in women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 2001, 86(6):2453-2455.
96. Kelly C.J., Speirs A., Gould G.W., Petrie J.R., Lyall H., Connell J.M. Altered vascular function in young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2002, 87(2):742-746.
97. Kiechl S., Schett G., Schwaiger J., et al. Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation 2007, 116(4):385-391.
98. Kim S.M., Lee J., Ryu O.H., et al. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin. Endocrinol. 2005, 63(5):594-598.
99. Knebel B., Janssen O.E., Hahn S., et al. Increased low grade inflammatory serum markers in patients with polycystic ovary syndrome (PCOS) and their relationship to PPAR gene variants. Exp. Clin. Endocrinol. Diabetes 2008, 116(8):481-486.
100. Koong A.C., Denko N.C., Hudson K.M., et al. Candidate genes for the hypoxic tumor phenotype. Cancer Res. 2000, 60(4):883-887.
101. Kowalska I., Straczkowski M., Szelachowska M., et al. Circulating Eselectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in men with coronary artery disease assessed by angiography and disturbances of carbohydrate metabolism. Metabolism 2002, 51(6):733-736.
102. Kowalska I., Straczkowski M., Nikolajuk A., et al. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum. Reprod. 2007, 22(7):1824-1829.
103. Kravariti M., Naka K.K., Kalantaridou S.N., et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2005, 90(9):5088-5095.
104. Lakhani K., Constantinovici N., Purcell W.M., Fernando R., Hardiman P. Internal carotid artery haemodynamics in women with polycystic ovaries. Clin. Sci. (Lond.) 2000, 98(6):661-665.
105. Legro R.S., Kunselman A.R., Dodson W.C., Dunaif A. Prevalence and predictor of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 264 affected women. J. Clin. Endocrinol. Metab. 1999, 84(1):165-169.
106. Legro R.S., Kunselman A.R., Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am. J. Med. 2001, 111(8):607-613.
107. Lewandowki K.C., Komorowski J., O'Callaghan C.J., et al. Increased circulating levels of matrix metalloproteinase-2 and -9 in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2006, 91(3):1173-1177.
108. Ley K., Huo Y. VCAM-1 is critical in atherosclerosis. J. Clin. Invest. 2001, 107(10):1209-1210.
109. Locatelli V., Rossoni G., Schweiger F., et al. Growth hormone independent cardioprotective effects of hexarelin in the rat. Endocrinology 1999, 140(9):4024-4031.
110. Loverro G., Lorusso F., Mei L., Depalo R., Cormio G., Selvaggi L. The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol. Obstet. Invest. 2002, 53(3):157-162.
111. Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 2007, 117(1):175-184.
112. Luque-Ramirez M., Mendieta-Azcona C., Alvarez-Blasco F., Escobar-Morreale H.F. Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Hum. Reprod. 2007, 22(12):3197-3203.
113. Luque-Ramirez M., Alvarez-Blasco F., Botella-Carretero J.I., Sanchon R., San Millan J.L., Escobar-Morreale H.F. The increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism, and do not result from reduced menstrual losses. Diabetes Care 2007, 30(9):2309-2313.
114. Makowski L., Hotamisligil G.S. The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr. Opin. Lipidol. 2005, 16(5):543-548.
115. Malyankar U.M., Scatena M., Suchland K.L., Yun T.J., Clark E.A., Giacchelli C.M. Osteoprotegerin is an alpha vbeta 3-induced. NF-kB-dependent survival factor for endothelial cells. J. Biol. Chem. 2000, 275(28):20959-20962.
116. Mather K.J., Verma S., Corenblum B., Anderson T.J. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2000, 85(5):1851-1856.
117. Meigs J.B., Hu F.B., Rifai N., Manson J.E. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004, 291(16):1978-1986.
118. Meyer C., McGrath B.P., Cameron J., Kotsopoulos D., Teede H.J. Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2005, 90(8):4630-4635.
119. Michiels C., Minet E., Mottet D., Raes M. Regulation of gene expression by oxygen: NF-kappaB and HIF-1, two extremes. Free Radic. Biol. Med. 2002, 33(9):1231-1242.
120. Minet E., Michel G., Mottet D., Raes M., Michiels C. Transduction pathways involved in hypoxia-inducible factor-1 phosphorylation and activation. Free Radic. Biol. Med. 2001, 31(7):847-855.
121. Möhlig M., Weickert M.O., Ghadamgadai E., et al. Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women. Eur. J. Endocrinol. 2007, 157(2):195-200.
122. Moller D.E. Potential role of TNF-[alpha] in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol. Metab. 2000, 11(6):212-217.
123. Moran L.J., Hutchison S.K., Meyer C., Zoungas S., Teede H.J. A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome. Clin. Sci. 2009, 116(10):761-770.
124. Morin-Papunen L., Rautio K., Ruokonen A., Hedberg P., Puukka M., Tapanainen J.S. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2003, 88(10):4649-4654.
125. Nagaya N., Moriya J., Yasumura Y., et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004, 110(24):3674-3679.
126. Nolan C.J., Madiraju M.S., Delghingaro-Augusto V., Peyot M.L., Prentki M. Fatty acid signaling in the beta-cell and insulin secretion. Diabetes 2006, 55(Suppl. 2):S16-S23.
127. Okamura K., Miura S., Zhang B., Uehara Y., Matsuo K., Kumagai K., et al. Ratio LDL- to HDL-associated platelet-activating factor acetylhydrolase may be a marker of inflammation in patients with paroxysmal atrial fibrillation. Circ. J. 2007, 71(2):214-219.
128. Orio F.J., Palomba S., Spinelli L., et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical prospective case-control study. J. Clin. Endocrinol. Metab. 2004, 89(8):3696-3701.
129. Orio F., Palomba S., Cascella T., et al. Is plaminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?. Reprod. Biomed. Online 2004, 9(5):505-510.
130. Orio F.J., Palomba S., Cascella T., et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2004, 89(9):4588-4593.
131. Orio F., Palomba S., Cascella T., et al. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2005, 90(1):2-5.
132. Orio F., Palomba S., Cascella T., et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J. Clin. Endocrinol. Metab. 2005, 90:6072-6076.
133. Orio F., Manguso F., Di Biase S., et al. Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study. Eur. J. Endocrinol. 2007, 157(1):69-73.
134. Page S.T., Herbst K.L., Amory J.K., Coviello A.D., Anawalt B.D., Matsumoto A.M., Bremner W.J. Testosterone administration suppresses adiponectin levels in men. J. Androl. 2005, 26(1):85-92.
135. Pagotto U., Gambineri A., Vicennati V., Heiman M.L., Tschöp M., Pasquali R. Plasma ghrelin, obesity and the polycystic ovary syndrome: correlation with insulin resistance and androgens levels. J. Clin. Endocrinol. Metab. 2002, 87(12):5625-5629.
136. Pai J.K., Pischon T., Ma J., et al. Inflammatory markers and the risk of coronary heart disease in men and women. N. Engl. J. Med. 2004, 351(25):2599-2610.
137. Pang J.J., Xu R.K., Xu X.B., et al. Hexarelin protects rat cardiomyocytes from angiotensin II-induced apoptosis in vitro. Am. J. Physiol. Heart Circ. Physiol. 2004, 286(3):H1063-H1069.
138. Pang C., Gao Z., Yin J., Zhang J., Jia W., Ye J. Macrophage infiltration into adipose tissue may promote angiogenesis for adipose tissue remodeling in obesity. Am. J. Physiol. Endocrinol. Metab. 2008, 295(2):E313-E322.
139. Panidis D., Farmakiotis D., Koliakos G., et al. Comparative study of plasma ghrelin levels in women with polycystic ovary syndrome, in hyperandrogenic women and in normal controls. Hum. Reprod. 2005, 20(8):2127-2132.
140. Panidis D., Farmakiotis D., Rousso D., et al. Plasma visfatin levels in normal weight women with polycystic ovary syndrome. Eur. J. Int. Med. 2008, 19(6):406-412.
141. Papandreou I., Cairns R.A., Fontana L., Lim A.L., Denko N.C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006, 3(3):187-197.
142. Pardo I.M., Geloneze B., Tambascia M.A., Pereira J.L., Barros Filho A.A. Leptin as a marker of sexual dimorphism in newborn infants. J. Pediatr. (Rio J.) 2004, 80(4):305-308.
143. Pasquali R., Gambineri A., Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 2006, 113(10):1148-1159.
144. Path G., Bornstein S.R., Ehrhart-Bornstein M., Scherbaum W.A. Interleukin-6 and the interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. J. Clin. Endocrinol. Metab. 1997, 82(7):2343-2349.
145. Pehlivanov B., Mitkov M. Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome. Eur. J. Contracept. Reprod. Health Care 2009, 14(2):153-159.
146. Peral B., San Millàn J.L., Castello R., Moghetti P., Escobar-Morreale H.F. The methionine 196 arginine polymorphism in exon 6 of the TNF receport 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism. J. Clin. Endocrinol. Metab. 2002, 87(8):3977-3983.
147. Poykko S.M., Kellokoski E., Horkko S., Kauma H., Kesaniemi Y.A., Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003, 52(10):2546-2553.
148. Rabinovitch A., Suarez-Pinzon W., Strynadka K., et al. Transfection of human pancreatic islets with an antiapoptotic gene (bcl-2) protects beta-cells from cytokine-induced destruction. Diabetes 1999, 48(6):1223-1229.
149. Rahmouni K., Morgan D.A., Morgan G.M., Mark A.L., Haynes W.G. Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes 2005, 54(7):2012-2018.
150. Rajendran S., Willoughby S.R., Chan W.P.A., et al. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis 2009, 204(2):509-514.
151. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease: detection and prevention. Circulation 2003, 107(3):363-369.
152. Rizvi A.A. Inflammation markers as mediators of vasculo-endothelial dysfunction and atherosclerosis in the metabolic syndrome. Chin. Med. J. (Engl.) 2007, 120(21):1918-1924.
153. Rizvi A.A. Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. Am. J. Med. Sci. 2009, 338(4):310-318.
154. Roby K.F., Terranova P.F. Effects of tumor necrosis factor-alpha in vitro on steroidogenesis of healthy and atretic follicles of the rat: theca as a target. Endocrinology 1990, 126(5):2711-2718.
155. Roldan V., Marin F., Lip G.Y., Blann A.D. Soluble E-selectin in cardiovascular disease and its risk factor. A review of the literature. Thromb. Haemost. 2003, 90(6):1007-1020.
156. Ross R. Atherosclerosis, an inflammatory disease. New Engl. J. Med. 1999, 340(2):115-126.
157. Rotter V., Nagaev I., Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-α, overexpressed in human fat cells from insulin-resistant subjects. J. Biol. Chem. 2003, 278(46):45777-45784.
158. Ruan H., Hacohen N., Golub T.R., Van Parijs L., Lodish H.F. Tumor necrosis factor alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes 2002, 51(5):1319-1336.
159. Saad M.F., Damani S., Gingerich R.L., et al. Sexual dimorphism in plasma leptin concentration. J. Clin. Endocrinol. Metab. 1997, 82(2):579-584.
160. Samy N., Hashim M., Sayed M., Said M. Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index. Dis. Markers 2009, 26(4):163-170.
161. Sathyapalan T., Kilpatrick E.S., Coady A.M., Atkin S.L. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J. Clin. Endocrinol. Metab. 2009, 94:103-108.
162. Scatena M., Giachelli C. The alpha vbeta 3 integrin, NF-kB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. Trends Cardiovasc. Med. 2002, 12(2):83-88.
163. Schoppert M., Preissner K.T., Hofbauer L.C. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler. Thromb. Vasc. Biol. 2002, 22(4):549-553.
164. Seftel A.D. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J. Urol. 2005, 174(3):1045-1046.
165. Sell H., Eckel J. Chemotactic cytokines, obesity and type 2 diabetes: in vivo and in vitro evidence for a possible causal correlation?. Proc. Nutr. Soc. 2009, 68(4):378-384.
166. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol. 2002, 64(5-6):993-998.
167. Semenza G.L., Agani F., Feldser D., et al. Hypoxia, HIF-1, and the pathophysiology of common human diseases. Adv. Exp. Med. Biol. 2000, 475:123-130.
168. Sengenès C., Miranville A., Lolmède K., Curat C.A., Bouloumié A. The role of endothelial cells in inflamed adipose tissue. J. Intern. Med. 2007, 262(4):415-421.
169. Senn J.J., Klover P.J., Nowak I.A., et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J. Biol. Chem. 2003, 278(16):13740-13746.
170. Shibata R., Ouchi N., Kihara S., Sato K., Funahashi T., Walsh K. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J. Biol. Chem. 2004, 279(27):28670-28674.
171. Shimizu Y., Nagaya N., Teranishi Y., et al. Ghrelin improves endothelial dysfunction through growth hormone-independent mechanisms in rats. Biochem. Biophys. Res. Commun. 2003, 310(3):830-835.
172. Sierra-Honigmann M.R., Nath A.K., Murakami C., et al. Biological action of leptin as an angiogenic factor. Science 1998, 281(5383):1683-1686.
173. Song M.J., Kim K.H., Yoon J.M., Kim J.B. Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem. Biophys. Res. Commun. 2006, 346(3):739-745.
174. Spaczynski R.Z., Arici A., Duleba A.J. Tumor necrosis factor-alpha stimulates proliferation of rat ovarian theca-interstitial cells. Biol. Reprod. 1999, 61(4):993-998.
175. Summers L.K., Samra J.S., Humphreys S.M., Morris R.J., Frayn K.N. Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. Clin. Sci. (Lond.) 1996, 91(6):679-683.
176. Talbott E., Guzick D., Clerici A., et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler. Thromb. Vasc. Biol. 1995, 15(7):821-826.
177. Talbott E.O., Zborowski J.V., Boudreaux M.Y., McHugh-Pemu K.P., Sutton-Tyrrell K., Guzick D.S. The relationship between C-reactive protein and carotid intima-media wall thickness in middleaged women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2004, 89(12):6061-6067.
178. Talbott E.O., Zborowski J.V., Rager J.R., Boudreaux M.Y., Edmundowicz D.A., Guzick D.S. Evidence for an association between metabolic syndrome cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2004, 89(11):5454-5461.
179. Tan B.K., Chen J., Digby J.E., Keavy S.D., Kennedy C.R., Randeva H.S. Increased visfatin mRNA and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome (PCOS): parallel increased in plasma visfatin. J. Clin. Endocrinol. Metab. 2006, 91(12):5022-5028.
180. Tarkun I., Arslan B.C., Canturk Z., Türemen E., Sahin T., Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J. Clin. Endocrinol. Metab. 2004, 89(11):5592-5596.
181. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 2004, 19(1):41-47. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group.
182. Thorand B., Kolb H., Baumert J., et al. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg study 1984-2002. Diabetes 2005, 54(10):2932-2938.
183. Tiras M.B., Yalcin R., Noyan V., et al. Alterations in cardiac flow parameters in patients with polycystic ovary syndrome. Hum. Reprod. 1999, 14(8):1949-1952.
184. Tosi F., Dorizzi R., Castello R., Maffeis C., Spiazzi G., Zoppini G., Muggeo M., Moghetti P. Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome. Eur. J. Endocrinol. 2009, 161(5):737-745.
185. Toulis K.A., Goulis D.G., Farmakiotis D., et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update 2009, 15(3):297-307.
186. Tschop M., Weyer C., Tataranni P.A., Devanarayan V., Ravussin E., Heiman M.L. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001, 50(4):707-709.
187. Ugur-Altun B., Altun A., Gerenli M., Tugrul A. The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity. Diabetes Res. Clin. Pract. 2005, 68(3):217-222.
188. Vgontzas A.N., Trakada G., Bixler E.O., et al. Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea. Metabolism 2006, 55(8):1076-1082.
189. Vicennati V., Gambineri A., Calzoni F., et al. Serum leptin in obese women with polycystic ovary syndrome is correlated with body weight and fat distribution but not with androgen and insulin levels. Metabolism 1998, 47(8):988-992.
190. Villuendas G., San Millàn J.L., Sancho J., Escobar-Morreale H.F. The -597G A and -174G C polymorphism in the promoter of the interleukin 6 gene (IL6) are associated with hyperandrogenism. J. Clin. Endocrinol. Metab. 2002, 87(3):1134-1141.
191. Vural B., Caliskan E., Turkoz E., Kilic T., Demirci A. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum. Reprod. 2005, 20(9):2409-2413.
192. Walch K., Grimm C., Zeillinger R., Huber J.C., Nagele F., Hefler L.A. A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndrome. Fertil. Steril. 2004, 81(June (6)):1638-1641.
193. Wijeyaratne C.N., Nirantharakumar K., Balen A.H., Barth J.H., Sheriff R., Belchetz P.E. Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity?. Clin. Endocrinol. (Oxf.) 2004, 60(5):560-567.
194. Xita N., Papassotiriou I., Geor giou I., Vounatsou M., Margeli A., Tsatsoulis A. The adiponectin-to-leptin ratio in women with polycystic ovary syndrome: relation to insulin resistance and proinflammatory markers. Metab. Clin. Exp. 2007, 56(6):766-771.
195. Xu X.F., De Per gola G., Bjorntorp P. Testosterone increases lipolysis and the number of beta-adrenoceptors in male rat adipocytes. Endocrinology 1991, 128(1):379-382.
196. Xu X.B., Cao J.M., Pang J.J., et al. The positive inotropic and calcium-mobilizing effects of growth hormone-releasing peptides on rat heart. Endocrinology 2003, 144(11):5050-5057.
197. Xu X.B., Pang J.J., Cao J.M., et al. GH-releasing peptides improve cardiac dysfunction and cachexia and suppress stress-related hormones and cardiomyocyte apoptosis in rats with heart failure. Am. J. Physiol. Heart Circ. Physiol. 2005, 289(4):H1643-H1651.
198. Xu X., Jhun B.S., Ha C.H., Jin Z.G. Molecular mechanism of ghrelin-mediated endothelial nitric oxide synthase activation. Endocrinology 2008, 149(8):4183-4192.
199. Yang A., Pizzulli L., Luderitz B. Mean platelet volume as a marker of restenosis after percutaneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris. Thromb. Res. 2006, 117(4):371-377.
200. Yarali H., Yildirir A., Aybar F., et al. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil. Steril. 2001, 76(3):511-516.
201. Yildiz B.O., Suchard M.A., Wong M.L., McCann S.M., Licinio J. Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(28):10434-10439.
202. Yilmaz M., Bukan N., Demirci H., et al. Serum resistin and adiponectin levels in women with polycystic ovary syndrome. Gynecol. Endocrinol. 2009, 25(4):246-252.
203. Ylmanaz M.B., Akin Y., Biyikoglu S.F., Guray U., Kisacik H.L., Korkmaz S. Left ventricular thrombosis is associated with increased mean platelet volume in patients with dilatated cardiomyopathy and sinus rhythm. Acta Cardiol. 2004, 59(1):41-45.
204. Yudkin J.S., Stehouwer C.D., Emeis J.J., Coppack S.W. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role of cytokines originating from adipose tissue?. Arterioscler. Thromb. Vasc. Biol. 1999, 19(4):972-978.
205. Zeyda M., Farmer D., Todoric J., et al. Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int. J. Obes. (Lond.) 2007, 31(9):1420-1428.
206. Zhao Y.F., Feng D.D., Chen C. Contribution of adipocyte-derived factors to beta cell dysfunction in diabetes. Int. J. Biochem. Cell Biol. 2006, 38(5-6):804-819.